Joshua Murtie
Elusys Therapeutics (United States)(US)
Publications by Year
Research Areas
HER2/EGFR in Cancer Research, Monoclonal and Polyclonal Antibodies Research, Neurogenesis and neuroplasticity mechanisms, Fibroblast Growth Factor Research, Epigenetics and DNA Methylation
Most-Cited Works
- → MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis(2016)424 cited
- → Presenilin-Dependent ErbB4 Nuclear Signaling Regulates the Timing of Astrogenesis in the Developing Brain(2006)343 cited
- → Loss of erbB signaling in oligodendrocytes alters myelin and dopaminergic function, a potential mechanism for neuropsychiatric disorders(2007)308 cited
- → Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway(2010)252 cited
- → MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by Reducing PRMT5-Dependent mRNA Splicing and Inducing DNA Damage(2021)224 cited
- → Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition(2017)160 cited
- → Fibroblast growth factor 2 (FGF2) and FGF receptor expression in an experimental demyelinating disease with extensive remyelination(2000)156 cited
- → PDGF and FGF2 pathways regulate distinct oligodendrocyte lineage responses in experimental demyelination with spontaneous remyelination(2005)152 cited
- → An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin(2013)122 cited
- → Dependence on the Pyrimidine Biosynthetic Enzyme DHODH Is a Synthetic Lethal Vulnerability in Mutant KRAS-Driven Cancers(2018)120 cited